Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer	Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma	Active, not recruiting	Phase 2	2026-10-08		NCT04675710

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
M.D. Anderson Cancer Center	1145

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cleveland Clinic Taussig Cancer Institute	Cleveland	United States	8
Huntsman Cancer Institute at the University of Utah	Salt Lake City	United States	20
M D Anderson Cancer Center	Houston	United States	667
Mayo Clinic	Rochester	United States	22
Stanford School of Medicine	Stanford	United States	1
University of Michigan Rogel Cancer Center	Ann Arbor	United States	186